Bristol Myers Squibb (BMY) recently experienced a
stock rise, spurred by a combination of positive results for its
schizophrenia drug, robust Q3 2024 earnings, and increased demand for its Eliquis and newly launched drugs. Despite an anticipated profit decline, BMS continues to see strong growth. Their
employees' effort in relaying miles cross-country to raise over $1 million exemplifies the company's commitment to
cancer research. Although some analysts remain cautious,
Jim Cramer considers their stock 'too low'. Q3 results display increased
revenue and
profit via drug sales, beating analyst estimates. Moreover,
U.S FDA approved the company’s Breyanzi as a new CAR T Cell Therapy for relapsed or refractory Mantle Cell Lymphoma. Albertsons (BMY) is enjoying increased attention from investors and gaining high strength ratings. Indeed, strategic acquisitions and overall
revenue increase seem to set the pharmaceutical giant on a trail of steady growth. Lastly, a 20% upside for Bristol Myers Squibb's stock is on the horizon due to the Cobenfy approval.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 02 Nov 2024 11:42:43 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor 2
